<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417818</url>
  </required_header>
  <id_info>
    <org_study_id>14-266-3</org_study_id>
    <nct_id>NCT02417818</nct_id>
  </id_info>
  <brief_title>Cutaneous Microcirculation After Plasma Therapy</brief_title>
  <official_title>Effects of Plasma Therapy in Cutaneous Microcirculation of Different Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In plastic and reconstructive surgery, treatment strategies of second-degree burns,&#xD;
      superficial wounds, burn scars, flaps and chronic wounds aim at reducing infection and&#xD;
      improving microcirculation. Although previous studies indicate that Plasma Therapy can&#xD;
      accelerate wound healing, only a few studies focused on the elucidation of its mechanisms of&#xD;
      action. Therefore, the aim of this study is to evaluate the microcirculatory effects of&#xD;
      Plasma Therapy on second-degree burns, superficial wounds, burn scars, flaps and chronic&#xD;
      wounds in a human in-vivo setting for the first time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microcirculation (composite measure)</measure>
    <time_frame>Baseline and 1 minute post-dose</time_frame>
    <description>capillary blood flow [arbitrary units AU]&#xD;
capillary blood velocity [AU]&#xD;
tissue oxygen saturation [%]&#xD;
relative postcapillary venous filling pressure [AU]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in microcirculation (areolar measure)</measure>
    <time_frame>Baseline, while and 1 minute post-dose</time_frame>
    <description>tissue oxygen saturation [%]&#xD;
tissue hemoglobin index</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Burn Injury</condition>
  <condition>Acute Wound</condition>
  <condition>Chronic Wound</condition>
  <condition>Burn Scar</condition>
  <arm_group>
    <arm_group_label>Second-Degree Burn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.&#xD;
Intervention: Plasma Therapy (PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Skin Excision (for Skin Graft)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.&#xD;
Intervention: Plasma Therapy (PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Wound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.&#xD;
Intervention: Plasma Therapy (PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intact Skin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.&#xD;
Intervention: Plasma Therapy (PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second-Degree Burn (repetitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Skin Excision (for Skin Graft) (repetitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Wound (repetitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intact Skin (repetitive)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertrophic burn scar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertrophic burn scar (repetitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flap (repetitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.&#xD;
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plasma Therapy (PlasmaDerm)</intervention_name>
    <description>Plasma Therapy (PlasmaDerm)</description>
    <arm_group_label>Chronic Wound</arm_group_label>
    <arm_group_label>Flap</arm_group_label>
    <arm_group_label>Hypertrophic burn scar</arm_group_label>
    <arm_group_label>Intact Skin</arm_group_label>
    <arm_group_label>Second-Degree Burn</arm_group_label>
    <arm_group_label>Skin Excision (for Skin Graft)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Plasma Therapy (repetitive PlasmaDerm)</intervention_name>
    <description>Repetitive Plasma Therapy (Repetitive PlasmaDerm)</description>
    <arm_group_label>Chronic Wound (repetitive)</arm_group_label>
    <arm_group_label>Flap (repetitive)</arm_group_label>
    <arm_group_label>Hypertrophic burn scar (repetitive)</arm_group_label>
    <arm_group_label>Intact Skin (repetitive)</arm_group_label>
    <arm_group_label>Second-Degree Burn (repetitive)</arm_group_label>
    <arm_group_label>Skin Excision (for Skin Graft) (repetitive)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group A (n=20): Consent-capable male and female patients ≥18 years of age who have&#xD;
        sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.&#xD;
&#xD;
        Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a&#xD;
        skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor&#xD;
        site must not be less than 1% of TBSA.&#xD;
&#xD;
        Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a&#xD;
        wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less&#xD;
        than 1% of TBSA.&#xD;
&#xD;
        Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving&#xD;
        as sham group. None of the the criteria of groups A-C must be evident. No soft tissue&#xD;
        injury must be evident.&#xD;
&#xD;
        Group E (n=20): Consent-capable male and female patients ≥18 years of age who have&#xD;
        sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.&#xD;
&#xD;
        Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a&#xD;
        skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor&#xD;
        site must not be less than 1% of TBSA.&#xD;
&#xD;
        Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a&#xD;
        wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less&#xD;
        than 1% of TBSA.&#xD;
&#xD;
        Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving&#xD;
        as sham group. None of the the criteria of groups E-G must be evident. No soft tissue&#xD;
        injury must be evident.&#xD;
&#xD;
        Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a&#xD;
        hypertrophic burn wound.&#xD;
&#xD;
        Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a&#xD;
        hypertrophic burn wound.&#xD;
&#xD;
        Group K (n=20): Consent-capable male and female patients ≥18 years of age received a flap.&#xD;
&#xD;
        Group L (n=20): Consent-capable male and female patients ≥18 years of age received a flap.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General exclusion criteria&#xD;
&#xD;
          -  below 18 years of age&#xD;
&#xD;
          -  wounds requiring artificial respiration, since consent for the study participation is&#xD;
             unobtainable&#xD;
&#xD;
        Exclusion criteria groups A, B, D, E, F, H:&#xD;
&#xD;
          -  peripheral arterial occlusive disease&#xD;
&#xD;
          -  vasculitis&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  chronic kidney or liver disease&#xD;
&#xD;
          -  cardiac dysfunction&#xD;
&#xD;
          -  arterial hypo- or hypertension&#xD;
&#xD;
        Anamnestic exclusion criteria&#xD;
&#xD;
          -  ongoing immunosuppressive or chemotherapy treatment&#xD;
&#xD;
          -  drug abuse&#xD;
&#xD;
          -  systemic skin diseases&#xD;
&#xD;
          -  systemic and local cortisone therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Kisch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Kisch, MD</last_name>
    <phone>00494515002063</phone>
    <email>tobias.kisch@uksh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Kisch, MD</last_name>
      <phone>00494515002063</phone>
      <email>tobias.kisch@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Tobias Kisch</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

